Evidence map›Paper›PMID 28987880›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2017

Heparin-functionalized polymer graft surface eluting MK2 inhibitory peptide to improve hemocompatibility and anti-neointimal activity.

Yunki Lee, Phuong Le Thi, Gyeung Mi Seon, Seung Bae Ryu, Colleen M Brophy, YongTae Kim, Jong-Chul Park, Ki Dong Park, Joyce Cheung-Flynn, Hak-Joon Sung

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Regenerative biomaterials · 2022
    Article
  5. Regenerative biomaterials · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Yunki LeeDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA.
Phuong Le ThiDepartment of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea.
Gyeung Mi SeonDepartment of Medical Engineering, Yonsei University College of Medicine, Seoul 03722, South Korea.
Seung Bae RyuDepartment of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea.
Colleen M BrophyDivision of Vascular Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
YongTae KimGeorge W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA.
Jong-Chul ParkDepartment of Medical Engineering, Yonsei University College of Medicine, Seoul 03722, South Korea.
Ki Dong ParkDepartment of Molecular Science and Technology, Ajou University, Suwon 16499, South Korea.
Joyce Cheung-FlynnDivision of Vascular Surgery, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Hak-Joon SungGeorge W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA; Severance Biomedical Science Institute, College of Medicine, Yonsei University, Seoul 03722, South Korea. Electronic address: hj72sung@yuhs.ac.
Ajou University · KRGeorgia Institute of Technology · USVanderbilt University Medical Center · USYonsei University · KRVanderbilt University · US

Funding

Thermosensitive injectable polymer-based stem cell therapy for limb ischemiaR21EB019509 · NIBIB · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SUNG, HAK-JOON, YOUNG, PAMPEE P · 2015 to 2016
$433k
NIBIB NIH HHS R21 EB019509
6 · The paper itself

Abstract

The leading cause of synthetic graft failure includes thrombotic occlusion and intimal hyperplasia at the site of vascular anastomosis. Herein, we report a co-immobilization strategy of heparin and potent anti-neointimal drug (Mitogen Activated Protein Kinase II inhibitory peptide; MK2i) by using a tyrosinase-catalyzed oxidative reaction for preventing thrombotic occlusion and neointimal formation of synthetic vascular grafts. The binding of heparin-tyramine polymer (HT) onto the polycarprolactone (PCL) surface enhanced blood compatibility with significantly reduced protein absorption (64.7% decrease) and platelet adhesion (85.6% decrease) compared to bare PCL surface. When loading MK2i, 1) the HT depot surface gained high MK2i-loading efficiency through charge-charge interaction, and 2) this depot platform enabled long-term, controlled release over 4weeks (92-272μg/mL of MK2i). The released MK2i showed significant inhibitory effects on VSMC migration through down-regulated phosphorylation of target proteins (HSP27 and CREB) associated with intimal hyperplasia. In addition, it was found that the released MK2i infiltrated into the tissue with a cumulative manner in ex vivo human saphenous vein (HSV) model. This present study demonstrates that enzymatically HT-coated surface modification is an effective strategy to induce long-term MK2i release as well as hemocompatibility, thereby improving anti-neointimal activity of synthetic vascular grafts.

Indexed as

AnimalsAnticoagulantsCell MovementCell ProliferationHeparinHumansMyocytes, Smooth MuscleNeointimaPeptidesPlatelet AdhesivenessPolyestersRats, Sprague-DawleySaphenous VeinThrombosisAnticoagulantsHeparinMK2i peptidePeptidespolycaprolactonePolyestersAnti-thrombosisHeparinIntimal hyperplasiaMK2 inhibitory peptideSynthetic vascular graftsTyrosinase-triggered surface functionalization

Identifiers

PMID28987880
PMCPMC5723561
OpenAlexW2762593451

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.